Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …

Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …

The binding of programmed death-1 (PD-1) on the surface of T cells and PD-1 ligand 1 (PD-
L1) on tumor cells can prevent the immune-killing effect of T cells on tumor cells and …

Since the discovery of immune checkpoint proteins, there has been a special interest in
developing antibodies that block programmed cell death 1 receptor (PD-1) and programmed …

Lung cancer is a major global health problem, as it is the leading cause of cancer-related
deaths worldwide. Major advances in the identification of key mutational alterations have led …

Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …

Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in a wide
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune
responses can regress tumors. However, this only occurs in a fraction of patients …